GNTA
Genenta Science S.p.A.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.91
P/S
0.00
EV/EBITDA
-1.58
DCF Value
$0.36
FCF Yield
-55.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-70.7%
ROA
-40.4%
ROIC
-43.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $0.00 | $-3.8M | $-0.20 |
| Q4 2024 | $0.00 | $-4.9M | $-0.27 |
| FY 2024 | $0.00 | $-8.9M | $-0.49 |
| Q2 2024 | $0.00 | $-4.0M | $-0.22 |
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
IT
Exchange
NASDAQ
Beta
0.61
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. The company was incorporated in 2014 and is headquartered in Milan, Italy.